GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (STU:RFS) » Definitions » Other Current Payables

Resverlogix (STU:RFS) Other Current Payables : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Resverlogix Other Current Payables?

Resverlogix's Other Current Payables for the quarter that ended in Dec. 2024 was €0.00 Mil.

Resverlogix's quarterly Other Current Payables increased from Jun. 2024 (€5.34 Mil) to Sep. 2024 (€5.69 Mil) but then declined from Sep. 2024 (€5.69 Mil) to Dec. 2024 (€0.00 Mil).


Resverlogix Other Current Payables Historical Data

The historical data trend for Resverlogix's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Other Current Payables Chart

Resverlogix Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Resverlogix Quarterly Data
Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 4.50 5.34 5.69 -

Resverlogix Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.


Resverlogix Other Current Payables Related Terms

Thank you for viewing the detailed overview of Resverlogix's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.


Resverlogix Business Description

Traded in Other Exchanges
Address
4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

Resverlogix Headlines

No Headlines